Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Power estimation for non-standardized multisite studies.
Biologics-induced autoimmune diseases.
ARESTIN®
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
β-Amyloid: Enemy or Remedy?
Insight into the mechanism of laquinimod action.
Gene Expression & Signaling in the Immune System
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Gordon Research Conference on Synaptic Dysfunction and Neurodegeneration
Studying both sexes: a guiding principle for biomedicine.

Pages

« first
‹ previous
…
96
97
98
99
100
101
102
103
104
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By